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Abstract: Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and co-
morbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause 
of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic 
preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render 
the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hy-
perlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the ef-
ficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by condi-
tioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding 
and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid 
conditions may lead to identification of novel molecular targets for cardioprotection.  
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1. ISCHEMIC CONDITIONING OF THE HEART  
Ischemic conditioning leads to remarkable cardioprotec-
tion against I/R injury (see for extensive reviews: [1, 2]). 
Ischemic conditioning has 3 major forms, preconditioning, 
postconditioning, and remote conditioning. In ischemic pre-
conditioning, brief episodes of ischemia/reperfusion are ap-
plied before a prolonged ischemic event that would other-
wise lead to significant irreversible tissue injury. Ischemic 
preconditioning is the most effective cardioprotective 
mechanism that evokes cardioprotection [3] immediately 
after triggering ischemia/reperfusion cycles and in a delayed 
manner (appearing 12-24 hours after the triggering ische-
mia/reperfusion cycles and lasting for approximately 72 
hours) the latter termed as the second window of protection 
[4]. In case of ischemic postconditioning, very brief episodes 
of ischemia/reperfusion are applied immediately after the 
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prolonged ischemic event. In remote ischemic conditioning, 
brief cycles of ischemia/reperfusion are applied to an ex-
tracardiac organ before, during, or after the prolonged 
ischemic event. The cardioprotective effect of pre-, post-, and 
remote conditioning has been well established in preclinical 
models as well as in clinical studies (see for reviews: [2, 5, 
6]), however, its effectiveness is limited by the presence of 
several risk factors, comorbidities, and co-medications (see 
for extensive reviews: [1, 7, 8]). Moreover, in spite of 3 dec-
ades of intense research on the cellular mechanism of condi-
tioning, it is still not completely understood. Therefore, no 
drug targets have been identified so far that led to the devel-
opment of a cardioprotective drug until market launching. 
This fact urges to find novel approaches to increase the trans-
lational value of preclinical studies (see for review [9]) and to 
find valid drug targets and novel therapeutic approaches for 
cardioprotection (see for review: [1, 10] and Table 1).  
In this review, we describe how assessment of changes in 
cardiac gene expression profile triggered by conditioning 
may facilitate the development of cardioprotective drugs that 
mimic the remarkable cardioprotection achieved by ischemic 
conditioning maneuvers. 
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Table 1. Examples for potential targets revealed by func-
tional genomics approaches. 
Target Role Reference 
Ischemic conditioning   
MAPKAP kinase 3 signaling [11] 
cathepsin G protease [11] 
PDE9A1 phosphodiesterase [12] 
peroxredoxin 4 antioxidant defence [18] 
PDGFR signaling [18] 
ZAC1 transcription factor [20] 
microRNA-139-5p unknown [17] 
microRNA-125b* unknown [17] 
let-7b unknown [17] 
microRNA-487b unknown [17] 
Hyperlipidemia and obesity   
ATF3 transcription factor [25] 
NADH-ubiquinone oxi-
doreductase 
energy metabolism [27] 
Hsp86 stress response [27] 
procollagen structural proteins [27] 
argininosuccinate synthetase Arg metabolism [28] 
Hsp70 stress response [28] 
cytochrome C oxidase energy metabolism [30] 
MMP-9 remodeling [30] 
microRNA-25 oxidative stress [33] 
microRNA-27b hypertrophy [34-36] 
Diabetes   
vanilloid receptor 1 signaling [64] 
histone deacetylase 2 gene regulation [64] 
apolipoprotein B lipid metabolism [64] 
MMP-13 remodeling [64] 
microRNA-208a hypertrophy [54, 55] 
microRNA-24 vascularization [54, 55] 
microRNA-21 hypertrophy [54, 55] 
 
2. GENE EXPRESSION OF THE HEART IN CARDIO-
PROTECTION BY ISCHEMIC CONDITIONING 
There is a continuously increasing interest in ischemic 
conditioning of the heart as shown by the increasing number 
of papers in PubMed. Although there are a total of more than 
ten thousand papers in the literature on cardioprotection by 
ischemic conditioning, less than 1% of these studies assessed 
global gene expression profile of the heart in response to 
ischemic conditioning. These studies have shown that pre-
conditioning and postconditioning significantly affect the 
gene expression profile of the ischemic heart at the transcript 
level. The first studies in the literature showing that early and 
late ischemic preconditioning affect gene expression profile 
of the heart using 1, 2 or 3 cycles of 5 min ischemia/5 min 
perfusion in rabbits and in isolated rat hearts, respectively, 
are more than 10 years old [11-13]. In rabbit hearts, 35 genes 
with significantly altered expression patterns in response to 
preconditioning were discovered including upregulated 
MAPKAP kinase 3 and cathepsin G genes in the precondi-
tioned region, and GTP exchange factor, Na+/K+-ATPase, Zn 
finger protein 35, cytochrome c oxidase, mitogen-responsive 
phosphoprotein, and Ran-binding protein in the non-
ischemic region [11]. In rat hearts, oligoadenylate synthase, 
chaperonin subunit epsilon, a cGMP phosphodiesterase 
(PDE9A1), a secretory carrier membrane protein, an amino 
acid transporter, and protease 28 subunit genes were changed 
in response to preconditioning [12].  
These early studies have been confirmed by several pa-
pers showing that both ischemic preconditioning and post-
conditioning trigger a cardioprotective gene expression pro-
file in the heart at the transcript level [14-17]. In line with 
these findings, changes in the expression of the post-
transcriptional regulators of gene expression, i.e. microRNAs 
have been recently shown by preconditioning and postcondi-
tioning in rat hearts [18]. Whether remote ischemic condi-
tioning may also affect global gene expression profile of the 
heart has not been specifically studied so far. Nevertheless, 
the early study of Simkhovich et al. [11] showing that the 
gene expression profile of the non-ischemic remote area was 
changed, suggests that remote conditioning also leads to a 
cardioprotective transcriptomic program. Accordingly, one 
paper has reported cardiac gene expression profile alterations 
following remote ischemic preconditioning; e.g. up-
regulation of genes involved in oxidative stress (e.g. perox-
iredoxin 4, platelet-derived growth factor receptor) 15 min or 
24 hours after 6 cycles of 4-min femoral artery occlu-
sion/reperfusion in mice [19]. In line with this assumption, 
extracellular vesicles, potential carriers of microRNAs, have 
been shown to mediate the cardioprotective effect of remote 
ischemic preconditioning induced by 3 × 5-5 min ische-
mia/reperfusion cycles in rat hearts [20].  
Identification of global gene expression profile of the 
heart in response to ischemic conditioning may help to iden-
tify key cellular pathways of ischemia/reperfusion injury and 
cardioprotection by ischemic conditioning. The transcription 
factor ZAC1 gene has been identified as potential target for 
gene silencing as this gene was significantly down-regulated 
by preconditioning and postconditioning [21]. Similarly, by 
a systematic comparison method looking at the direction of 
microRNA expression changes after ischemia/reperfusion 
injury with or without preceding preconditioning or subse-
quent postconditioning, respectively, potential cardioprotec-
tive microRNA targets have been identified and termed “pro-
tectomiRs”, e.g. mimics of microRNA-139-5p, -125b*, let-
7b, and antagomiR of microRNA-487b in rat hearts [18]. 
Functional Genomics of Cardioprotection Current Drug Targets, 2015, Vol. 16, No. 7    3 
These preclinical results show that by assessing the cardio-
protective gene expression profile of the heart subjected to 
ischemia/reperfusion with or without cardioprotection elic-
ited by ischemic conditioning, novel targets for cardioprotec-
tion can be identified. However, no data on the cardioprotec-
tive gene expression fingerprints in the human heart are 
available so far. 
3. INFLUENCE OF CO-MORBIDITIES ON CARDIAC 
GENE EXPRESSION PATTERN  
The mechanism by which the remarkable cardioprotec-
tive effect of ischemic conditioning is attenuated or abol-
ished in the presence of major cardiovascular risk factors and 
comorbidities as well as their routine drug treatments is not 
exactly known (see for extensive reviews: [1, 7, 8]). There-
fore, for successful cardioprotective target identification and 
validation, it is of great importance to assess the effect of 
major cardiovascular comorbidities and co-medications such 
as dyslipidemia, diabetes, hypertension, obesity, aging etc 
(see for review: [1]). Accentuated myocardial oxidative 
stress has been reported in the presence of major comorbid-
ities. Therefore, it is plausible to speculate that redox signal-
ing-dependent global gene expression changes contribute to 
the pathological phenotypes. The redox-sensitive modulation 
of gene expression may occur both by direct oxida-
tive/nitrative modification of the transcription factor itself or 
by posttranslational modifications (i.e. mainly phosphoryla-
tion/dephosphorylation] due to alterations in redox-regulated 
intracellular signaling cascades (e.g. p38 MAPK) [22]. So far 
limited amount of data have been accumulated in the litera-
ture regarding the effect of hyperlipidemia, obesity, and dia-
betes on cardiac gene expression profile, while there are still 
negligible data on other cardiovascular risk factors and co-
morbidities. In this chapter we will review the current data 
available in the literature on the effect of major cardiovascu-
lar comorbidities on cardiac gene expression profile, focus-
ing on metabolic diseases such as hyperlipidemia, obesity 
and diabetes.  
3.1. Hyperlipidemia, Obesity and Statins 
Hyperlipidemia and obesity are amongst the most im-
portant risk factors for cardiovascular diseases due to their 
steeply increasing prevalence worldwide. Moreover, hyper-
lipidemia was the first risk factor to be associated with the 
loss of cardioprotection by ischemic preconditioning in 
rabbits and rats on chronic cholesterol-enriched diet ([23, 
24], see for the first extensive review [8]). Since then, it has 
been well established that most of the other major risk fac-
tors and their medications may modify cardioprotective 
signaling [1, 7]. Therefore, to better characterize the effect 
of these pathologies on the heart and to uncover novel 
therapeutic targets, several research groups have performed 
systematic analyses of cardiac gene expression in various 
disease models. 
A few publications aimed to decipher how the composi-
tion of consumed excess fat influences gene expression in 
the heart. Lockridge and colleagues hypothesized that expo-
sure to various fatty acids alone have differential effect on 
the gene expression pattern of isolated cardiomyocytes. They 
compared effects of fatty acids considered cardioprotective 
and cardiotoxic by cDNA microarrays and revealed that 24 h 
treatment of saturated fatty acids tended to induce endoplas-
mic reticulum- and oxidative stress markers (e.g. activating 
transcription factor 3 or growth arrest and DNA-damage-
inducible protein α) more than a treatment with unsaturated 
fatty acids [25]. The acute effects of unsaturated fatty acids 
on gene expression in the heart were studied in-vivo as well. 
Mice were fed with triglycerides comprising specific fatty 
acids, and 6 hour later mRNA expression profiles of the 
hearts were determined. Similarly to the experiment on iso-
lated cells, a differential modulation of gene expression was 
shown, where linolenic acid (C18:3) modulated the expres-
sion of most genes, the majority of which was related to the 
PPARα signaling pathway (e.g. heme oxygenase 1 or angio-
poietin-like 4 protein) [26]. These studies clearly demon-
strate that even a short term overload of dietary fats might 
modulate cardiac gene expression, and that these effects are 
specific to fatty acid moieties and most likely not a direct 
consequence of the cellular energy imbalance. 
Long term effects of hyperlipidemia and obesity on car-
diac gene expression has been studied in several papers. In 
an early study, Puskas et al reported that in the hearts of rats 
on cholesterol-enriched chow for two months expression of 
numerous genes were modulated, including members of en-
ergy metabolism (e.g. NADH-ubiquinone oxidoreductase), 
heat shock proteins (heat shock protein 86), ion channels 
(sodium/potassium ATPase), and structural proteins (procol-
lagen, type III, α1) [27]. Later, Sarkozy et al described dif-
ferences in gene expression between Zucker diabetic fatty 
and control lean rats including several metabolic enzymes 
(e.g. argininosuccinate synthetase), stress response proteins 
(e.g. heat shock protein 70, 1A) and ion channels (e.g. so-
dium/potassium ATPase β4 polypeptide) [28]. Several of 
these genes have not been implicated in cardiovascular dis-
eases before. Tissue specific gene expression changes were 
also compared in obese animals [29]. In high-fat chow fed 
mice expression of several hundred genes is altered, although 
only a fraction of them is common between tissues. In the 
heart most robust changes were detected in members of lipid 
metabolism (e.g. major urinary proteins 2, 3 and 5), but in 
contrast, in the adipose tissue expression of several genes of 
the immune system were altered (e.g. CD84 antigen). In addi-
tion, a profound modulation of PPAR signaling in most tis-
sues is shown in this publication, similarly to others, e.g. [26].  
Large animal models have been rarely used for cardiac 
transcriptomics studies. Rouet and colleagues investigated 
dogs after 9 weeks of high fat diet that lead to approximately 
25% weigh gain and arterial hypertension. This treatment 
resulted in a profound alteration of atrial and ventricular 
gene expression [30]. They identified several metabolic en-
zymes (e.g. cytochrome C oxidase), ion channels (e.g. so-
dium/potassium ATPase), genes involved in protein synthe-
sis and remodeling (e.g. matrix metalloprotease 9, or nuclear 
factor erythroid 2–related factor 2). Interestingly, most gene 
expression changes have been detected in the atria and not 
the left ventricle. For example, they assessed a decrease in 
phospholamban and sarco-endoplasmic reticulum Ca2+-
ATPase-2 (SERCA-2) mRNA level only in the atria. In a 
following study, they studied temporal changes in gene ex-
pression as well. Dogs were fed with high-fat chow for 9-24 
weeks and left ventricular mRNA levels were assessed by 
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microarrays [31]. In these experiments they identified a time-
dependent decrease in the ventricular expression of phospho-
lamban and SERCA-2. At 24 weeks they also found a de-
crease in myostatin expression, and an up-regulation in the 
expression of several genes related to the TGF-β pathway, 
which are also implicated in obesity-related cardiac patholo-
gies, such as hypertrophy and excessive fibrosis. 
The effect of human obesity or hyperlipidemia on cardiac 
gene expression patterns is not well studied. Philip-Couderc 
et al investigated mRNA transcript levels from right atrial 
appendages of obese and lean patients. They reported that 
obesity modulates the expression of almost 400 genes in the 
heart, and showed that the most affected signaling pathway 
was the down-regulated Wnt system, which is involved in 
cardiac hypertrophy [32]. Although this report shows that the 
gene expression pattern of the human atrium is severely al-
tered in obesity, so far data is unavailable from ventricular 
samples. Given that the overlap in reported gene expression 
changes between species and models seem to be low, studies 
on obesity- and hyperlipidemia-modulated gene expression 
is still warranted. 
During the last decade an increasing number of research-
ers directed their focus on the systematic analysis of miR-
NAs in the cardiovascular system. We recently reported that 
expression of several miRNAs is altered in the ventricles of 
rats fed a cholesterol-enriched chow [33]. One of the most 
robust down-regulation was found in miR-25, which might 
be responsible for the increased oxidative- and nitrosative 
stress observed in this model, since one of the putative tar-
gets of miR-25 is NOX4, a major source of reactive oxygen 
species. The role of miRNAs in hyperlipidemia- and obesity-
induced changes in gene expression was also studied in the 
liver of mice on high-fat diet [34]. They found that hepatic 
expression of miR-27b is elevated in obese animals. The 
study concluded that miR-27b is a key regulator of hepatic 
lipid metabolism since the expression of its several target 
genes were also altered in hyperlipidemia. One might sug-
gest that cardiac lipid metabolism can also be influenced by 
miRNAs through the circulation. Indeed, it has been reported 
that the overexpression of miR-27b leads to cardiac dysfunc-
tion and hypertrophy in mice [35], however, elsewhere it was 
identified as an anti-hypertrophic miRNA [36]. As in case of 
mRNA transcriptomics studies, data on cardiac expression of 
miRNAs in hyperlipidemic or obese humans is missing. 
Statins, as inhibitors of 3-hydroxy-3-methyl glutaryl co-
enzyme A reductase, are potent cholesterol-lowering drugs 
that are widely used in clinical practice for primary and sec-
ondary prevention of coronary heart disease. Statins can ex-
ert pleiotropic effects aside from lowering cholesterol and 
blood pressure through several different pathways including 
the induction of endothelial nitric-oxide synthase expression, 
anti-inflammatory actions, and antioxidant activity [37]. We 
have previously shown in isolated rat hearts that lovastatin 
interferes with the anti-ischemic effect of ischemic pre- and 
postconditioning [38]. However, only a handful of preclini-
cal studies investigated the effects of statin treatment on car-
diac gene expression pattern. In a comparative study differ-
ent types of statins such as atorva-, prava-, pitava-, and rosu-
vastatin were administered orally to normal C57Bl/6 mice 
for 4 weeks [39]. The authors found altogether 49 genes to 
be up- or down-regulated by statin treatments in a drug-
specific manner, from which tissue inhibitor of metalloprote-
inases-3 showed the most robust increase in response to 
atorvastatin treatment. Others reported on cardiac expression 
changes of 93 genes after 4-week atorvastatin [15 
mg/kg/day) treatment in normal Wistar Kyoto rats, whilst 
cardiac mRNA level of 60 genes has been altered by the 
same treatment in stroke prone spontaneously hypertensive 
rats [40]. The altered genes included several ones involved in 
general metabolic pathways (glucose, fatty acid, and choles-
terol biosynthesis, etc.), cell division, signaling, motility, 
cell/organism defense, regulation of protein expression, oxi-
dative stress, and inflammatory processes. Despite the abun-
dance of clinical studies investigating the effects of statins, 
comprehensive studies on the effect of statins on cardiac 
gene expression profiles in the healthy and ischemic human 
myocardium are still missing. 
3.2. Diabetes 
Diabetes-related metabolic and molecular alterations ul-
timately lead to complex and serious cardiovascular compli-
cations, involving accelerated progression of atherosclerosis 
and deterioration of cardiac function [41). Diabetic myocar-
dial dysfunction and diabetic cardiomyopathy is the factor 
that is responsible for higher cardiac morbidity and mortality 
in diabetics [42]. It is well established now that multiple fac-
tors contribute and promote to the development and evolu-
tion of diabetic cardiomyopathy (these include hyperglyce-
mia and subsequent insulin resistance, increased fatty acid 
metabolism, microcirculatory changes, sympathetic dysfunc-
tion, myocardial inflammation, oxidative/nitrative stress, 
remodeling and fibrosis), however the exact molecular 
events that initiate and fuel these pivotal pathological 
mechanisms are not entirely clear [43]. To understand the 
underlying biological processes and identify new molecular 
targets, detailed characterization of gene expression in these 
hearts with systems biological tools is of high importance. 
Investigations in pre-diabetic models are clinically essen-
tial, due to the enormously increasing incidence and overlap-
ping prevalence of metabolic syndrome and pre-diabetes 
[44]. There is also evidence for the deterioration of myocar-
dial function in models of pre-diabetes [45-47], in line with 
these, recently we have reported marked global gene expres-
sion alterations in the heart Zucker diabetic fatty rats [28], a 
model that is characterized by main features of pre-diabetes 
and metabolic syndrome (obesity, hyperglycemia, hyperinsu-
linemia, and hypercholesterolemia). Among the 14921 tran-
script assessed, 10244 showed detectable expression in the 
heart. Altogether 85 transcripts showed significant altera-
tions (up- or down-regulation), when compared to the lean 
control rats. The detailed analysis (involving functional clus-
terization and gene ontology analysis) showed alterations in 
transcripts of lipid metabolism (e.g. 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 2; argininosuccinate 
synthetase; 2-amino-3-ketobutyrate-coenzyme A ligase), 
extra- and intracellular structural proteins (e.g. myosin IXA; 
aggrecan1), signal transduction (e.g. activating transcription 
factor 3; phospholipase A2) stress response (e.g. heat shock 
70kD protein 1A; heat shock protein 60; glutathione S-
transferase Yc2 subunit), ion channels and receptors (e.g. 
ATPase, Na+/K+ transporting, beta 4 polypeptide; ATPase, 
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H+/K+ transporting, non-gastric, alpha polypeptide). These 
profound modifications in the cardiac transcriptome might be 
involved in the development of cardiac pathological abnor-
malities induced by pre-diabetes and metabolic syndrome.  
Similar comprehensive studies were carried out in recent 
years in different models of overt diabetes, either using ge-
netic models of the disease (Goto-Kakizaki diabetic rats, 
Otsuka Long-Evans Tokushima fatty rats) or the streptozoto-
cin-induced type I. diabetes model. Karakikes et al. revealed 
significant divergence in myocardial gene expression profile 
in the hearts of the diabetic Otsuka Long-Evans Tokushima 
fatty rats when compared to the non-diabetic controls [48]. 
Out of the 20500 transcripts surveyed, 838 showed divergent 
expression (272 up-regulations and 566 down-regulations). 
Their subsequent functional analysis indicates that diabetic 
cardiomyopathy in this type 2 diabetes model is associated 
with changes in transcripts involved in immunity, develop-
ment, intracellular signaling, cell proliferation and transcrip-
tion regulation.  
There is also evidence for the profound effect of diabetes 
on deteriorated post-infarction remodeling. The adverse re-
modeling process in diabetes is in association with profound 
myocardial gene expression alterations. The study by Song et 
al. suggest that in type 1 diabetic rats transcriptomic changes 
are responsible for altered myocardial metabolic substrate 
utilization (affected fatty acid metabolism, carboxylic acid 
synthesis, steroid metabolisms), that may account for the 
exaggerated progression of post-infarction remodeling proc-
esses [49].  
Gestational diabetes is a specific diabetic condition, af-
fecting both the health of the-mother and the baby. Although, 
there is a three- to four fold increase in the incidence of con-
genital heart defects caused by maternal diabetes [50], the 
exact molecular mechanisms that contribute to the terato-
genic effects of the diabetic milieu are not known. A recent 
study investigated gene expression profiles of developing 
hearts of embryos, aiming to shed light on the mechanisms 
of cardiac malformation development [51]. The study re-
vealed several differentially expressed genes in healthy and 
diabetic embryonic hearts. Based on the functional categori-
zation of the altered transcripts it is hypothesized that genes 
involved in lipid metabolism, cell cycle and transcription 
regulation have important role in cardiac embryopathy.  
Although, transcriptomic tools have revealed several im-
portant gene expression alterations in the heart in diabetic 
conditions, several limitations have to be noted. In the last 
years it became evident that the fate of the mRNA is deter-
mined by presence of other regulatory non-coding RNA spe-
cies (e.g. microRNAs). In addition the importance and extent 
of alternative splicing events in cardiac pathologies are now 
recognized [52] that are impossible to assess with conven-
tional microarray-based tools. In line with these, reactivation 
of the fetal splicing gene program has been described by 
Verma et al. [53]. RNA sequencing and subsequent bioin-
formatics identification of splicing events revealed that sev-
eral important transcripts implicated in diabetes (e.g. VEGF, 
Mef2a) undergo alternative splicing. In addition there is a 
significant similarity of splicing pattern in the diabetic and 
developing embryonic heart, indicating the reprogramming 
of fetal gene expression events. 
Recent studies also indicate the importance of microR-
NAs in the development of diabetic myocardial pathologies. 
The concordant studies of the Hu lab indicate striking altera-
tions in microRNA expression profile in the heart of strepto-
zotocin treated rats, implicating alterations in whole gene 
networks [54, 55]. They identified 19 microRNAs that were 
dysregulated in diabetic hearts (up-regulation of miR-195, 
miR-199a-3p, miR-142-3p, miR-24, miR-21, miR-208a, 
miR-221, miR-499-3p, miR-700, and miR-705 and down-
regulation of miR-1, miR-143, miR-29, miR-20a, miR-220b, 
and miR-373). Based on bioinformatic target prediction and 
partial experimental validation, it seems that the affected 
microRNAs have a significant fingerprint on myocardial 
transcriptomic profile (affected genes involve hypertrophy- 
and fibrosis-related targets). 
In addition, accumulating evidence proves the applicabil-
ity of microRNAs as diagnostic biomarkers. In a landmark 
study Zampetaki et al. determined plasma microRNA ex-
pression profiles in diabetic patients [56], revealing 5 candi-
date microRNAs (miR-15a, miR-29b, miR-126, miR-223, 
and miR-28-3p) to be used as diagnostic indicators and pre-
dictors of later onset diabetes. Another study recently ad-
dressed altered circulating miRNA levels in children with 
type I diabetes; here interestingly levels of miR-126 were 
predominantly down in urine but not plasma of patients sug-
gesting more pathological involvement of the kidney in re-
sponse to type I diabetes [57). 
The prevalence of diabetic neuropathy is greater than 
50% in patients with long-standing diabetes [58]. Although, 
several papers have been published investigating the gene 
expression changes in different neural structures during the 
development of diabetic neuropathy, it is not clear if diabetes 
affects cardiac gene expression due to sensory and/or motor 
neuropathy. Capsaicin, an essential compound of hot pepper, 
is used as topical treatment to alleviate severe pain in pa-
tients with diabetic neuropathy [59]. Capsaicin is a highly 
selective sensory neurotoxin that leads to a selective func-
tional blockade of a primary sensory neurons [60, 61]. We 
have previously shown that capsaicin-sensitive sensory 
nerves play an important role in preconditioning in rat hearts 
[62]. Furthermore, we demonstrated that capsaicin-sensitive 
nerves are involved in the regulation cardiac NO-cGMP sig-
naling [63], which is known to be one of the major regula-
tory pathways for ischemic conditioning. Moreover, we have 
also shown that selective chemodenervation of capsaicin-
sensitive sensory nerves in male Wistar rats in vivo, beyond 
cardiac diastolic dysfunction, induced changes in myocardial 
gene expression [64]. In this study, among the 6400 rat genes 
examined by DNA microarray and/or by QRT-PCR, 47 
genes exhibited significant up-regulation and 36 were down-
regulated. The up-regulated genes affect neural functions 
(e.g. vanilloid receptor 1; GABA receptor rho-3 subunit), 
signal transduction (including NO signaling), cell adhesion 
(integrin α v subunit), gene regulation (histone deacetylase 
2), and metabolic pathways particularly the lipid (apolipo-
protein B, farnesyl transferase) metabolism. Among the re-
pressed genes we have also found genes of metabolic path-
ways (e.g. aldehyde dehydrogenase), cell cycle regulators 
(cyclin-dependent kinase 4), matrix metalloproteinase 13, 
and interleukin 7. 
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CONCLUSION AND PERSPECTIVE 
By assessing global cardiac gene expression profile of 
the ischemic heart with or without cardioprotection by 
ischemic conditioning, one may explore the cardioprotective 
gene expression fingerprint and identify novel drug targets 
for cardioprotection (Table 1). However, for identification of 
valid drug targets, the effect of cardiovascular risk factors, 
comorbidities, and co-medications of ischemic heart disease 
should be taken into account. There is also an unmet need for 
studies that utilize an integrated “omics” approach (mRNA 
and non-coding RNA transcriptomics followed by proteomic 
analysis) with subsequent robust bioinformatics (e.g. net-
work analysis) to identify key regulatory networks and sig-
naling hubs in response to cardioprotection (Fig. (1) [65, 
66]). This approach may provide the basis of cardioprotec-
tive gene threrapy as well [67]. So far very few studies 
looked at changes in the gene expression profile of the 
ischemic heart in response to cardioprotection and its con-
founding factors. However, such studies would be necessary 
to identify key pathways of cardioprotection that are still 
active in the presence of major cardiovascular comorbidities 
and their routine medications.  
LIST OF ABBREVIATIONS 
I/R = Ischemia/reperfusion 
MAPKAP kinase = Mitogen-activated protein kinase-
activated protein kinase 
Mef2 = Myocyte enhancer factor-2 
NO-cGMP = Nitric oxide, cyclic GMP 
NOX4 = NADPH oxidase 4 
PPARα = Peroxisome proliferator-activated 
receptor alpha 
QRT-PCR = Quantitative real time polymerase  
SERCA-2 = Sarco-endoplasmic reticulum Ca2+-
ATPase-2 
VEGF = Vascular endothelial growth factor 
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